You are here

Article info

Article menu

Download PDFPDF

Poster Presentations
12. Young researchers session
P12.11 RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients

Authors

  • S Egea-Rodriguez Department of Dermatology and Allergy, University Hospital of Munich, Ludwig-Maximilian-University (LMU), Munich, Germany German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • R Váraljai Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany PubMed articlesGoogle scholar articles
  • TM Nordmann Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany PubMed articlesGoogle scholar articles
  • R Lubis Lead Discovery Center GmbH (LDC), Dortmund, Germany PubMed articlesGoogle scholar articles
  • M Philip Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany PubMed articlesGoogle scholar articles
  • F Rambow Department of Applied Computational Cancer Research, Institute for AI in Medicine (IKIM), University Hospital Essen, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles
  • A Roesch Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany PubMed articlesGoogle scholar articles
  • D Schadendorf Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany German Cancer Consortium (DKTK), Partner Site Essen/Düsseldorf, Essen, Germany PubMed articlesGoogle scholar articles
  • B Klebl Lead Discovery Center GmbH (LDC), Dortmund, Germany PubMed articlesGoogle scholar articles
  • ID Hickson Center for Chromosome Stability and Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark PubMed articlesGoogle scholar articles
  • M Mann Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany PubMed articlesGoogle scholar articles
  • S Horn Rudolf Schönheimer Institute of Biochemistry, Medical Faculty of the University of Leipzig, Leipzig, Leipzig, Germany PubMed articlesGoogle scholar articles
  • I Helfrich Department of Dermatology and Allergy, University Hospital of Munich, Ludwig-Maximilian-University (LMU), Munich, Germany German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany Skin Cancer Unit of the Dermatology Department, Medical Faculty, West German Cancer Center, University Duisburg-Essen, Essen, Germany PubMed articlesGoogle scholar articles

Citation

Egea-Rodriguez S, Váraljai R, Nordmann T, et al
P12.11 RECQL4 promotes immune evasion and limits response to anti-PD-1 therapy and survival in melanoma patients
Journal for ImmunoTherapy of Cancer 2024;12:doi: 10.1136/jitc-2024-ITOC10.65
Online issue publication 
March 20, 2024

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.